INNATE PHARMA News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

05.10.23	Innate Pharma Provides Update on Lacutamab Clinical Program (Businesswire)
14.09.23	Innate Pharma Reports First Half 2023 Financial Results and Business Update (Businesswire)
29.08.23	Innate Pharma Announces Its Participation to Upcoming Investor Conferences and Conference Call for First Half 2023 Business Update (Businesswire)
10.08.23	Innate Pharma to Participate in Upcoming Investor Conference (Businesswire)
11.07.23	First Patient Dosed in SAR’514 / IPH6401 Phase 1/2 Clinical Trial in Relapsed/Refractory Multiple Myeloma (Businesswire)
07.07.23	Number of Shares and Voting Rights of Innate Pharma as of July 1, 2023 (Businesswire)
26.06.23	First Patient Dosed in Phase 2 MATISSE Trial of IPH5201 in Early Stage Lung Cancer (Businesswire)
16.06.23	Innate Pharma Highlights Increased Lacutamab Clinical Activity From Interim Results of Phase 2 TELLOMAK Study With Updated Olsen Criteria (Businesswire)
12.06.23	Innate Pharma to Present Updated Interim Phase 2 Efficacy Results of Lacutamab in Mycosis Fungoides at the International Conference on Malignant Lymphoma (Businesswire)
10.06.23	Innate Pharma Highlights Proprietary Tetra-specific ANKET® NK Cell Engager IPH6501 at the EHA 2023 Congress (Businesswire)
08.06.23	SAR’579 / IPH6101 Receives FDA Fast Track Designation in the US for the Treatment of Hematological Malignancies (Businesswire)
07.06.23	Number of Shares and Voting Rights of Innate Pharma as of June 1, 2023 (Businesswire)
26.05.23	Innate Pharma Highlights Phase 1/2 Dose Escalation Safety and Preliminary Efficacy of Sanofi Developed First NK Cell Engager SAR’579 / IPH6101 in R/R AML (Businesswire)
23.05.23	Innate Pharma to Participate in Upcoming Investor Conferences (Businesswire)
15.05.23	Innate Pharma to Present IPH6501 Preclinical Data at The EHA 2023 Congress (Businesswire)
12.05.23	Outcome of Innate Pharma’s 2023 Annual General Meeting (Businesswire)
10.05.23	Innate Pharma Reports First Quarter 2023 Financial Results and Business Update (Businesswire)
09.05.23	Number of shares and voting rights of Innate Pharma as of May 1, 2023 (Businesswire)
03.05.23	Innate Pharma Announces Conference Call and Webcast for Q1 Business Update (Businesswire)
03.05.23	Innate Pharma Highlights Clinical Abstracts Selected for ASCO 2023 Annual Meeting (Businesswire)
26.04.23	Innate Pharma Establishes a New At-The-Market ("ATM”) Program on Nasdaq (Businesswire)
21.04.23	Innate Pharma to Participate in Upcoming Investor Conference (Businesswire)
18.04.23	Number of Shares and Voting Rights of Innate Pharma as of April 1, 2023 (Businesswire)
07.04.23	Innate Pharma to Hold Its Annual General Meeting of Shareholders on May 12, 2023 (Businesswire)
06.04.23	Innate Pharma Files Its 2022 Universal Registration Document (Document d’enregistrement universel) and 2022 Annual Report on Form 20-F (Businesswire)
03.04.23	Innate Pharma Announces Exclusive License of Antibodies to Takeda for Celiac Disease Research Program (Businesswire)
23.03.23	Innate Pharma Reports Full Year 2022(1) Financial Results and Business Update (Businesswire)
20.03.23	Number of Shares and Voting Rights of Innate Pharma as of March 1, 2023 (Businesswire)
16.03.23	Innate Pharma Announces Conference Call and Webcast for Full Year 2022 Financial Results (Businesswire)
13.03.23	Innate Pharma Provides Update on Silicon Valley Bank Exposure (Businesswire)
21.02.23	Number of Shares and Voting Rights of Innate Pharma as of February 1, 2023 (Businesswire)
07.02.23	Innate Pharma to Participate in Upcoming Investor Conferences (Businesswire)
25.01.23	Innate Pharma Announces HSR Clearance Regarding Expansion of Its Collaboration With Sanofi on NK Cell Engagers (Businesswire)
16.01.23	Innate Pharma Announces Publication of Preclinical Data with a Trifunctional NK Cell Engager in Acute Myeloid Leukemia in Nature Biotechnology (Businesswire)
19.12.22	Sanofi and Innate Pharma Expand Collaboration for Natural Killer Cell Therapeutics in Oncology (Businesswire)
10.12.22	Innate Pharma Presents Data From Ongoing Phase 2 TELLOMAK Trial Demonstrating Clinical Activity of Lacutamab in Advanced Sézary Syndrome at ASH 2022 (Businesswire)
09.12.22	Number of Shares and Voting Rights of Innate Pharma as of December 1, 2022 (Businesswire)
01.12.22	Innate Pharma to present adenosine franchise, IPH5201 and IPH5301 at ESMO IO 2022 (Businesswire)
14.11.22	Innate Pharma Reports Third Quarter Financial Results (Businesswire)
07.11.22	Innate Pharma Announces Conference Call and Webcast for Third Quarter 2022 Business Update (Businesswire)
04.11.22	Innate Pharma to Present Results From a Preliminary Analysis of the TELLOMAK Phase 2 Trial in Patients With Advanced Sezary Syndrome and ANKET™ Platform at ASH 2022 (Businesswire)
02.11.22	Innate Pharma to Participate in Upcoming Investor Conferences (Businesswire)
20.10.22	Innate Pharma 2023 Financial Calendar (Businesswire)
23.09.22	Innate Pharma Presents Data From Ongoing Phase 2 TELLOMAK Trial Demonstrating Clinical Activity of Lacutamab in Advanced Mycosis Fungoides (Businesswire)
15.09.22	Innate Pharma Reports First Half 2022 Financial Results and Business Update (Businesswire)
08.09.22	Innate Pharma Announces Conference Call and Webcast for First Half 2022 Business Update (Businesswire)
05.09.22	Innate Pharma to Present Lacutamab PTCL Phase 1b Design and ANKET™ Platform at ESMO 2022 (Businesswire)
23.08.22	Innate Pharma to Participate in Upcoming Investor Conferences (Businesswire)
08.08.22	Number of Shares and Voting Rights of Innate Pharma as of August 1, 2022 (Businesswire)
01.08.22	Innate Pharma Provides Update on AstraZeneca-Sponsored INTERLINK-1 Phase 3 Study (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Part Grp Hldg	1’263.50	2.89 %	K V
Sonova Hldg	312.10	2.66 %	K V
Novartis	93.68	2.32 %	K V
Geberit	526.80	1.97 %	K V
Roche Hldg G	254.30	1.27 %	K V
Kuehne+Nagel Int	209.50	0.72 %	K V
UBS Group	28.30	0.57 %	K V
Givaudan	3’933.00	0.36 %	K V
Nestle	76.00	0.05 %	K V
Lonza Grp	521.40	-0.04 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu INNATE PHARMA SA

Aktien Top/Flop

Meistgelesene Nachrichten